threonine tyrosine kinase inhibitor CFI-402257

{
  "id": "MLC-T-ONC-017150",
  "term": "threonine tyrosine kinase inhibitor CFI-402257",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable, selective inhibitor of the dual specificity protein kinase TTK (monopolar spindle 1 kinase, Mps1), with potential antineoplastic activity. Upon administration, luvixasertib selectively binds to and inhibits the activity of Mps1. This inactivates the spindle assembly checkpoint (SAC) and accelerates mitosis, which results in chromosomal misalignment and missegregation, and mitotic checkpoint complex destabilization. This induces cell death in Mps1-overexpressing cancer cells. Mps1, a tyrosine and serine/threonine kinase expressed in proliferating normal tissues, is essential for proper SAC functioning and chromosome alignment. Overexpressed in various human tumors, Mps1 plays a key role in uncontrolled tumor cell growth.",
  "synonyms": [
    "TTK inhibitor CFI-402257",
    "MSP1 inhibitor CFI-402257"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/threonine-tyrosine-kinase-inhibitor-cfi-402257/"
}